Trilogy is a modern hybrid strain derived from Triple OG. Its precise origin remains undocumented, and breeders have not publicly confirmed a complete lineage or the specific development history of the variety. Because the breeding background is not formally established, growers should view the strain as a standalone offering within the contemporary hybrid market. It is cultivated in both indoor and outdoor environments, with a moderate difficulty level and a reported 60-day flowering cycle that results in high yields.

The aromatic and flavor profile of Trilogy is characterized by a complex, multi-layered terpene expression. The profile is led by terpinolene, followed closely by myrcene and caryophyllene. It further features a diverse secondary and tertiary array of ocimene, limonene, humulene, beta-pinene, pinene, linalool, bisabolol, gamma-terpinene, nerolidol, alpha-terpinene, caryophyllene-oxide, sabinene, valencene, eucalyptol, p-cymene, borneol, camphene, and geraniol. While these components are confirmed, the overall intensity of the sensory experience reflects an estimated concentration of these compounds that influences the strain’s specific aromatic nuance.

In terms of chemical potency, Trilogy contains an estimated THC concentration of approximately 18.8%, with CBD and CBG levels estimated at 0%. Users typically report experiencing effects of relaxation, happiness, and a sense of being uplifted. Given these properties, the strain is often utilized for addressing stress, pain, and sleep-related concerns. Currently, there are no recorded offspring attributed to Trilogy in the public record.